OR WAIT null SECS
February 04, 2022
ABPI has responded to the publication of a white paper on ‘Levelling Up’ by the government of the United Kingdom.
Zetta Genomics has raised £2.5 million ($3.4 million) in new seed funding.
Janssen has submitted a MAA to the EMA for teclistamab as a treatment of relapsed or refractory multiple myeloma (RRMM).
pharmasol has completed the strategic merger with PharmaLex.
Pharming Group has announced positive results from the Phase II/III study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).
The UK’s NICE issued a Final Appraisal Document recommending marketing authorization for AstraZeneca’s chronic kidney disease treatment, Forxiga (dapagliflozin).
February 03, 2022
Although mRNA and viral vector vaccines have been top of mind for COVID-19 treatments, other technologies and treatments are emerging—along with new variants.
February 02, 2022
Eli Lilly and Company is investing $1 billion to establish a new manufacturing site in Concord, NC, to manufacture parenteral products and devices.
Eli Lilly and Company has entered into a research and collaboration agreement with Entos Pharmaceuticals to develop new therapeutics for treating neurologic disorders.
The global nature of the COVID-19 pandemic emphasizes the critical importance of expanded vaccination.